Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth

This article was originally published in The Gray Sheet

Executive Summary

“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.

You may also be interested in...



HeartWare Touts Early Success In U.S. Launch Of HVAD

HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.

Pressure Builds In Ventricular Assist Market

With only two companies, Thoratec and HeartWare International, selling LVADs in the US, clinical data along with sales and product pipeline strategies have become paramount for capturing market share – and expanding the market to treat a wide range of class III heart failure patients.

Study In Circulation Questions Cost Effectiveness Of VADs

A recent analysis of the cost effectiveness of ventricular assist devices used as destination therapy for heart failure suggests room for improvement.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel